Huntingtin (HTT)

Pathway Diagram

flowchart TD
    HUNTINGTIN["HUNTINGTIN"]
    style HUNTINGTIN fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0
    ALS["ALS"]
    HUNTINGTIN -->|"associated with"| ALS
    Frontotemporal_Dementia["Frontotemporal Dementia"]
    HUNTINGTIN -->|"associated with"| Frontotemporal_Dementia
    Dementia["Dementia"]
    HUNTINGTIN -->|"associated with"| Dementia
    Amyotrophic_Lateral_Sclerosis["Amyotrophic Lateral Sclerosis"]
    HUNTINGTIN -->|"associated with"| Amyotrophic_Lateral_Sclerosis
    Spinocerebellar_Ataxia["Spinocerebellar Ataxia"]
    HUNTINGTIN -->|"associated with"| Spinocerebellar_Ataxia
    Ataxia["Ataxia"]
    HUNTINGTIN -->|"associated with"| Ataxia
    Aging["Aging"]
    HUNTINGTIN -->|"regulates"| Aging
    Alzheimer["Alzheimer"]
    HUNTINGTIN -->|"regulates"| Alzheimer
    style ALS fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style Frontotemporal_Dementia fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style Dementia fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style Amyotrophic_Lateral_Sclerosis fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style Spinocerebellar_Ataxia fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style Ataxia fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style Aging fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style Alzheimer fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0

Overview

Huntingtin (HTT) is a large protein encoded by the HTT gene, most famous for its role in Huntington’s disease where CAG repeat expansion in the first exon leads to mutant huntingtin (mHTT). However, wild-type huntingtin is a multifunctional protein essential for normal neuronal function, involved in vesicle trafficking, transcription regulation, mitochondrial function, and synaptic plasticity.^{1A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes1993 · Cell · PMID 8504315Open reference}

Huntingtin is one of the largest proteins in the human proteome (~350 kDa), with over 3,000 amino acids. It is ubiquitously expressed with particularly high levels in the brain. The protein contains multiple HEAT repeat domains that mediate protein-protein interactions, allowing huntingtin to serve as a scaffold for various signaling complexes.^{2The HEAT repeat and Huntington disease2002 · Trends in Neurosciences · PMID 11925566Open reference}

The discovery of huntingtin in 1993 revolutionized Huntington’s disease research, shifting focus from transcriptional dysregulation to understanding how mutant protein gains toxic functions while losing normal protective functions. This duality makes huntingtin a unique therapeutic target.^{3Huntington disease: pathogenesis, treatment, and research directions2014 · American Journal of Human Genetics · DOI 10.1016/j.ajhg.2014.03.018Open reference}

Domain Architecture and Molecular Structure

Polyglutamine (PolyQ) Tract

The N-terminal region contains the polyglutamine (polyQ) tract—the molecular basis of Huntington’s disease:

• Normal range: 10-35 glutamine residues

• Reduced penetrance: 36-39 glutamines

• Full penetrance: ≥40 glutamines

• Anticipation: Earlier onset in subsequent generations correlates with paternal transmission^{4A correlation between CAG repeat length and age of onset in Huntington disease2004 · American Journal of Human Genetics · PMID 15286788Open reference}

The polyQ expansion leads to abnormal protein conformation, aggregation, and toxic gain-of-function. The threshold of ~36-40 glutamines represents a critical transition point where the protein shifts from functional to pathogenic.^{5Polyglutamine toxicity is controlled by protein conformation2000 · Cell · PMID 10978864Open reference}

HEAT Repeat Domains

Huntingtin contains ~23 HEAT (Huntingtin, Elongin A, Ternary complex factor) repeats throughout the protein:

• HEAT repeats: ~40 amino acid alpha-helical segments that mediate protein-protein interactions

• Scaffold function: Enable huntingtin to assemble multi-protein signaling complexes

• Binding partners: Interact with over 100 proteins including molecular motors, transcription factors, and signaling proteins^{2The HEAT repeat and Huntington disease2002 · Trends in Neurosciences · PMID 11925566Open reference}

• Pathology impact: Mutations affect HEAT repeat interactions, disrupting normal complexes^{6HEAT repeat protein dynamics and function2010 · Current Opinion in Structural Biology · PMID 19837036Open reference}

Polyproline Region

Immediately downstream of the polyQ tract:

• Proline-rich sequence: Mediates interactions with SH3 domain-containing proteins

• Structural role: Provides flexibility between the polyQ tract and functional domains

• Functional impact: Important for normal protein interactions and localization^{7Polyproline and polyalanine interactions in huntingtin2002 · Journal of Molecular Biology · PMID 11835573Open reference}

C-Terminal Functional Domains

The C-terminal region contains:

• WW domain: Protein interaction module binding to PPxY motifs

• Nuclear export signal: Facilitates cytoplasmic localization

• ** caspase cleavage sites**: Multiple sites cleaved during apoptosis^{8Caspase cleavage of mutant huntingtin2003 · Journal of Neuroscience · PMID 14502205Open reference}

Normal Cellular Functions

Vesicle Trafficking and Transport

Wild-type HTT is essential for intracellular transport:

• Molecular motor scaffold: Directly binds dynein, kinesin, and dynactin complexes^{9Huntingtin facilitates dynein-dynactin transport2007 · Proceedings of the National Academy of Sciences · PMID 17942211Open reference}

• Organelle trafficking: Facilitates movement of vesicles, mitochondria, and endosomes

• Axonal transport: Critical for long-range transport in neurons

• Synaptic vesicle dynamics: Regulates vesicle cycling at presynaptic terminals^{2The HEAT repeat and Huntington disease2002 · Trends in Neurosciences · PMID 11925566Open reference}0

The transport function explains why neurons—with their extreme morphological complexity—are particularly vulnerable to HTT dysfunction.

Transcriptional Regulation

Huntingtin interacts with multiple transcription pathways:

• REST/NRSF complex: Normal HTT sequesters REST in the cytoplasm; mutant HTT releases REST to translocate to nucleus^{2The HEAT repeat and Huntington disease2002 · Trends in Neurosciences · PMID 11925566Open reference}1

• p53 function: Modulates p53-dependent transcription and apoptosis

• NF-κB signaling: Influences inflammatory gene expression

• CREB-mediated transcription: Affects activity-dependent gene expression^{2The HEAT repeat and Huntington disease2002 · Trends in Neurosciences · PMID 11925566Open reference}2

Mitochondrial Function

Huntingtin maintains mitochondrial health:

• Mitochondrial dynamics: Regulates fission and fusion proteins

• Quality control: Supports mitophagy and mitochondrial biogenesis

• Calcium homeostasis: Manages mitochondrial calcium buffering

• Energy metabolism: Influences ATP production and mitochondrial membrane potential^{2The HEAT repeat and Huntington disease2002 · Trends in Neurosciences · PMID 11925566Open reference}3

Synaptic Function

At synapses, huntingtin regulates:

• Neurotransmitter release: Modulates vesicle fusion and release probability

• Receptor trafficking: Affects AMPA, NMDA, and GABA receptor trafficking

• Dendritic spine morphology: Influences spine density and structure

• Synaptic plasticity: Regulates long-term potentiation and depression^{2The HEAT repeat and Huntington disease2002 · Trends in Neurosciences · PMID 11925566Open reference}4

Cell Survival and Neuroprotection

Wild-type HTT has anti-apoptotic properties:

• Bcl-2 interaction: Binds and inhibits pro-apoptotic Bcl-2 family proteins

• Caspase inhibition: Direct interactions with caspases reduce activation

• Trophic support: Promotes BDNF production and secretion

• DNA repair: Supports base excision repair pathways^{2The HEAT repeat and Huntington disease2002 · Trends in Neurosciences · PMID 11925566Open reference}5

Pathogenic Mechanisms in Huntington’s Disease

Aggregation and Proteostasis

Mutant huntingtin forms multiple aggregate species:

• Nuclear inclusions: Ubiquitinated aggregates in neuronal nuclei

• Cytoplasmic aggregates: Include huntingtin-positive aggregates, dysmorphic mitochondria, and autophagic vacuoles

• Oligomeric species: Soluble oligomers may represent the most toxic species

• Seeding capability: Aggregates can propagate in a prion-like manner^{2The HEAT repeat and Huntington disease2002 · Trends in Neurosciences · PMID 11925566Open reference}6

The proteostasis machinery (ubiquitin-proteasome system and autophagy) becomes overwhelmed, leading to broader cellular dysfunction.

Transcriptional Dysregulation

Multiple transcriptional pathways are affected:

• REST dysregulation: Nuclear translocation of REST leads to repression of neuronal genes^{2The HEAT repeat and Huntington disease2002 · Trends in Neurosciences · PMID 11925566Open reference}7

• PGC-1α dysfunction: Impaired mitochondrial biogenesis through PGC-1α suppression

• Dysregulated microRNAs: Multiple miRNA alterations affect gene expression

• Chromatin remodeling: Altered histone modifications and DNA methylation patterns^{2The HEAT repeat and Huntington disease2002 · Trends in Neurosciences · PMID 11925566Open reference}8

Mitochondrial Dysfunction

Multiple mitochondrial abnormalities occur:

• Complex I deficiency: Reduced NADH dehydrogenase activity

• ATP depletion: Reduced cellular energy capacity

• Calcium mishandling: Impaired mitochondrial calcium buffering

• ROS production: Increased oxidative stress

• Drp1-mediated fission: Enhanced mitochondrial fragmentation^{2The HEAT repeat and Huntington disease2002 · Trends in Neurosciences · PMID 11925566Open reference}9

Axonal Transport Defects

Transport impairments begin early and worsen with disease progression:

• Motor protein dysfunction: Mutant HTT disrupts dynein-dynactin function

• Vesicle trafficking deficits: Reduced BDNF and synaptic vesicle transport

• Organelle transport failure: Impaired mitochondrial and lysosomal trafficking

• Distal axon vulnerability: Particularly affected are distal regions of long-projecting neurons^{3Huntington disease: pathogenesis, treatment, and research directions2014 · American Journal of Human Genetics · DOI 10.1016/j.ajhg.2014.03.018Open reference}0

Synaptic Dysfunction

Early synaptic changes precede neurodegeneration:

• Excitotoxicity: Enhanced NMDA receptor sensitivity

• Spine loss: Reduced dendritic spine density

• Transmission deficits: Altered GABAergic and glutamatergic signaling

• Network dysfunction: Disrupted cortical-striatal connectivity^{3Huntington disease: pathogenesis, treatment, and research directions2014 · American Journal of Human Genetics · DOI 10.1016/j.ajhg.2014.03.018Open reference}1

Disease Associations and Therapeutic Implications

Huntington’s Disease (Primary)

HTT mutations cause Huntington’s disease:

• Autosomal dominant inheritance: Single mutant allele is sufficient

• ** CAG repeat expansion**: Length correlates with age of onset (inversely)

• Full penetrance: ≥40 CAG repeats leads to disease

• Anticipation: Paternal transmission typically expands repeats^{3Huntington disease: pathogenesis, treatment, and research directions2014 · American Journal of Human Genetics · DOI 10.1016/j.ajhg.2014.03.018Open reference}2

Other Neurodegenerative Diseases

Huntingtin dysfunction contributes to other conditions:

• Alzheimer’s disease: HTT cleavage products found in AD brains; may interact with amyloid pathways^{3Huntington disease: pathogenesis, treatment, and research directions2014 · American Journal of Human Genetics · DOI 10.1016/j.ajhg.2014.03.018Open reference}3

• Parkinson’s disease: Altered HTT expression in PD models

• Spinocerebellar ataxias: Similar polyglutamine mechanisms

• ALS: HTT modifications influence TDP-43 pathology^{3Huntington disease: pathogenesis, treatment, and research directions2014 · American Journal of Human Genetics · DOI 10.1016/j.ajhg.2014.03.018Open reference}4

Cancer

Huntingtin has complex relationships with cancer:

• Elevated HTT in tumors: Some carcinomas show increased HTT expression

• Metastasis support: May facilitate cell migration

• Therapeutic targeting: HTT-lowering approaches in clinical trials may have oncological implications^{3Huntington disease: pathogenesis, treatment, and research directions2014 · American Journal of Human Genetics · DOI 10.1016/j.ajhg.2014.03.018Open reference}5

Therapeutic Approaches and Drug Development

HTT-Lowering Strategies

The primary therapeutic approach is reducing mutant HTT:

• Antisense oligonucleotides (ASOs): Multiple clinical trials completed (e.g., Tominersen, others)^{3Huntington disease: pathogenesis, treatment, and research directions2014 · American Journal of Human Genetics · DOI 10.1016/j.ajhg.2014.03.018Open reference}6

• RNA interference (RNAi): AAV-delivered shRNA approaches in development

• Small molecule inhibitors: Targeting HTT transcription or translation

• CRISPR-based approaches: Gene editing strategies advancing^{3Huntington disease: pathogenesis, treatment, and research directions2014 · American Journal of Human Genetics · DOI 10.1016/j.ajhg.2014.03.018Open reference}7

Targeting Downstream Pathways

Multiple pathway-targeted approaches:

• Aggregation inhibitors: Preventing mutant HTT aggregation

• Caspase inhibitors: Blocking HTT cleavage

• Transcription modulators: REST and other transcription factor targets

• Mitochondrial protectants: Enhancing mitochondrial function^{3Huntington disease: pathogenesis, treatment, and research directions2014 · American Journal of Human Genetics · DOI 10.1016/j.ajhg.2014.03.018Open reference}8

Symptomatic Treatments

Current care includes:

• Tetrabenazine/Deutetrabenazine: VMAT2 inhibitors for chorea

• Antidepressants: For mood symptoms

• Physical therapy: Maintaining function

• Speech therapy: Managing dysarthria^{3Huntington disease: pathogenesis, treatment, and research directions2014 · American Journal of Human Genetics · DOI 10.1016/j.ajhg.2014.03.018Open reference}9

Disease-Modifying Pipeline

Key programs in development:

• Gene therapy: AAV-delivered HTT-targeting constructs

• RNA therapies: Multiple ASO and siRNA programs

• Small molecule modulators: Various mechanisms in preclinical/clinical stages

• Cell therapy: Stem cell approaches for neuronal replacement^{4A correlation between CAG repeat length and age of onset in Huntington disease2004 · American Journal of Human Genetics · PMID 15286788Open reference}0

Biomarkers and Outcome Measures

Biomarker Categories

Multiple biomarker types are being validated:

• Fluid biomarkers: Neurofilament light chain (NfL), tau, mutant HTT in CSF

• Imaging biomarkers: Volumetric MRI, FDG-PET, Pittsburg compound B PET

• Digital biomarkers: Quantitative movement assessments

• Genetic markers: CAG repeat length for onset prediction^{4A correlation between CAG repeat length and age of onset in Huntington disease2004 · American Journal of Human Genetics · PMID 15286788Open reference}1

Clinical Outcome Measures

Standard endpoints include:

• Unified Huntington’s Disease Rating Scale (UHDRS): Total functional capacity, motor score

• HD-CAB: Cognitive and behavioral assessments

• Quality of life measures: HD-QoL, SF-36

• Caregiver burden scales: Measuring impact on families^{4A correlation between CAG repeat length and age of onset in Huntington disease2004 · American Journal of Human Genetics · PMID 15286788Open reference}2

Model Systems and Research Tools

Cellular Models

Key model systems include:

• Patient-derived iPSCs: Differentiated to neurons, medium spiny neurons

• Stable cell lines: Expressing mutant HTT fragments or full-length

• Primary neuron cultures: From transgenic mice or human tissue

• Organoid systems: Brain organoids for developmental studies^{4A correlation between CAG repeat length and age of onset in Huntington disease2004 · American Journal of Human Genetics · PMID 15286788Open reference}3

Animal Models

Multiple model organisms are used:

• Mouse models: R6/2, HD100, BACHD, and others with various mutation types

• Pig models: Larger brain size more closely mimics human

• Non-human primates: For most translationally relevant data

• Drosophila: For genetic screens and rapid iteration^{4A correlation between CAG repeat length and age of onset in Huntington disease2004 · American Journal of Human Genetics · PMID 15286788Open reference}4

Research Techniques

Important methodologies:

• CRISPR/Cas9: For generating precise knock-in models

• Proteomics: Identifying HTT interaction networks

• Single-cell RNA-seq: Profiling cellular heterogeneity

• Live-cell imaging: Visualizing transport and aggregation^{4A correlation between CAG repeat length and age of onset in Huntington disease2004 · American Journal of Human Genetics · PMID 15286788Open reference}5

Outstanding Questions

1. What is the normal function of HTT?: Despite decades of study, full understanding eludes us

2. What is the most toxic species?: Oligomers, aggregates, or loss of function?

3. How does polyQ expansion cause toxicity?: Multiple mechanisms, but relative importance unclear

4. Why are specific neurons vulnerable?: Striatal medium spiny neurons show earliest degeneration

5. Can mutant HTT be safely lowered in humans?: Clinical trials showed mixed results

6. What is the relationship between CAG repeat and phenotype?: Modifiers influence onset and progression

Evidence Grading

• Strong: HTT mutations cause HD with complete genetic validation

• Strong: Multiple downstream pathogenic mechanisms demonstrated in models

• Strong: Therapeutic targeting of HTT shows target engagement in trials

• Moderate: Relationship to other neurodegenerative diseases

• Moderate: Biomarkers for disease progression^{4A correlation between CAG repeat length and age of onset in Huntington disease2004 · American Journal of Human Genetics · PMID 15286788Open reference}6

See Also

• HTT Gene

• Huntington’s Disease

• Polyglutamine Diseases

• Axonal Transport Mechanism

• Mitochondrial Dysfunction

• Transcriptional Dysregulation

Brain Atlas Resources

The following resources from the Allen Brain Atlas provide expression and connectivity data for this protein/gene:

• Allen Human Brain Atlas - Gene Expression: Searchable gene expression database from adult human brain

• Allen Brain Atlas - RNA Sequencing: RNA sequencing data across brain regions

• Allen Cell Type Atlas: Single-cell transcriptomic data for cell type classification

• Allen Mouse Brain Atlas: Comprehensive mouse brain gene expression database

• BrainSpan Atlas of the Developing Human Brain: Developmental expression data across brain regions and ages

External Links

• UniProt: HTT

• PubMed: HTT

• HGNC: HTT

• OMIM: 143100

Genetic Epidemiology and Population Genetics

Global Distribution

Huntington’s disease occurs worldwide with varying prevalence:

• European ancestry: 5-10 per 100,000; highest prevalence

• Asian populations: 0.5-1 per 100,000; lower but significant

• African populations: Limited data; estimates suggest similar to Asian

• Founder mutations: Several isolated populations with high incidence[^35]

Founder Effects

Specific populations show founder effects:

• Venezuela: Lake Maracaibo region has world’s highest prevalence (~1 in 100)

• Scotland: Particular regions show elevated rates

• Tasmania: Historical founder effect

• South Africa: Specific mutations traced to European settlers[^36]

Genetic Counseling

Key counseling considerations:

• Predictive testing: Available for at-risk individuals

• Prenatal testing: For couples at risk

• Preimplantation genetic diagnosis: IVF-based selection

• Family planning: Support for reproductive decision-making[^37]

Neuropathology

Gross Pathology

Characteristic findings at autopsy:

• Striatal atrophy: Most prominent in caudate nucleus and putamen

• Cortical involvement: Variable cortical thinning

• Subcortical changes: Pallidum, thalamus, and hypothalamus affected

• Lateral ventricular enlargement: Secondary to tissue loss[^38]

Microscopic Pathology

Key histological features:

• Neuronal loss: Medium spiny neurons most affected

• Neuronal intranuclear inclusions: Huntingtin-positive, ubiquitinated

• Astrocytic gliosis: Reactive astrocytosis in affected regions

• White matter changes: Demyelination and axonal loss[^39]

Regional Vulnerability

Specific brain regions show differential vulnerability:

• Striatum: Most severely affected; medium spiny neurons degenerate first

• Layer 5 cortical neurons: Significant involvement

• Hippocampal CA1: Variable involvement

• Cerebellum: Relatively spared until late stages[^40]

Clinical Presentation and Disease Course

Early Stage

Initial symptoms typically include:

• Motor manifestations: Chorea (involuntary movements), dystonia

• Cognitive changes: Executive dysfunction, slowed processing

• Behavioral changes: Depression, irritability, apathy

• Weight loss: Often significant despite adequate intake[^41]

Middle Stage

Disease progression leads to:

• Chorea intensification: May become functionally limiting

• Motor impairment: Bradykinesia, incoordination

• Cognitive decline: Progressive dementia

• Behavioral symptoms: Psychiatric manifestations intensify[^42]

Late Stage

Advanced disease features:

• Rigidity: Akinesia predominates

• Severe cognitive impairment: Global dementia

• Communication loss: Speech and language breakdown

• Nutritional failure: Requires assisted feeding[^43]

Juvenile-Onset Huntington Disease

When CAG repeats exceed ~60:

• Earlier onset: Typically before age 20

• Parkinsonian features: More prominent than chorea

• Cognitive decline: Often rapid progression

• Seizures: More common in juvenile cases[^44]

Diagnosis and Clinical Evaluation

Diagnostic Criteria

Standard diagnostic approach:

• Clinical diagnosis: Motor symptoms + family history

• Genetic confirmation: CAG repeat expansion ≥36

• Exclusion of phenocopies: Rule out other causes

• Anticipation awareness: Consider earlier onset in offspring[^45]

Differential Diagnosis

Conditions to exclude:

• Other movement disorders: Parkinson’s, essential tremor

• Psychiatric conditions: Schizophrenia, bipolar disorder

• Other dementias: Alzheimer’s, FTD

• Metabolic disorders: Wilson’s disease, thyroid disease[^46]

Clinical Assessment Tools

Key evaluation instruments:

• UHDRS: Unified Huntington’s Disease Rating Scale

• TFC: Total Functional Capacity

• Motor examination: Standardized scoring

• Cognitive testing: Battery for executive function[^47]

Management and Supportive Care

Multidisciplinary Approach

Optimal care involves multiple specialties:

• Neurology: Movement disorder specialists

• Psychiatry: For behavioral management

• Physical therapy: Movement and balance

• Speech therapy: Communication support

• Nutrition: Dietary management[^48]

Pharmacological Management

Current medication approaches:

• Tetrabenazine: VMAT2 inhibitor, first-line for chorea

• Deutetrabenazine: Improved tolerability

• Valbenazine: Once-daily option

• Antipsychotics: For behavioral symptoms[^49]

Non-Pharmacological Interventions

Important supportive measures:

• Exercise: Maintain physical function

• Cognitive stimulation: Support mental activity

• Nutritional support: Maintain weight

• Home modifications: Safety adaptations[^50]

Research Directions and Future Therapies

Gene Therapy Approaches

Viral vector-based strategies:

• AAV delivery: Engineered AAV vectors for CNS targeting

• Antisense delivery: Direct CNS administration

• Gene editing: CRISPR-based approaches in development

• Allele-specific targeting: Mutant allele-selective approaches[^51]

Cell-Based Therapies

Cell replacement strategies:

• Neural stem cells: Embryonic or induced sources

• Medium spiny neuron differentiation: Directed differentiation

• Surgical transplantation: Early trials showed some promise

• Immunomodulation: Supporting cell survival[^52]

Biomarker Development

Critical research priorities:

• Mutant HTT detection: Sensitive detection in biofluids

• Neurofilament markers: NfL as progression marker

• Imaging markers: MRI and PET biomarkers

• Digital biomarkers: Wearable device integration[^53]

Clinical Trial Design

Innovative trial approaches:

• Premanifest trials: Treating before symptoms

• Platform trials: Adaptive designs

• Biomarker enrichment: Patient selection

• Combination endpoints: Multiple outcome measures[^54]

Comparative Biology and Evolution

HTT Homologs

Huntingtin is evolutionarily conserved:

• Rodent models: Highly similar sequence (~86% identity)

• Zebrafish: Functional ortholog exists

• Drosophila: Single ortholog present

• C. elegans: Distant homolog identified^{4A correlation between CAG repeat length and age of onset in Huntington disease2004 · American Journal of Human Genetics · PMID 15286788Open reference}7

Evolutionary Conservation

Key domains are highly conserved:

• PolyQ tract: Length varies across species

• HEAT repeats: Conserved structure and function

• Nuclear export signal: Maintained across species

• Functional domains: Largely conserved^{4A correlation between CAG repeat length and age of onset in Huntington disease2004 · American Journal of Human Genetics · PMID 15286788Open reference}8

Species-Specific Considerations

Research model implications:

• Mouse: Similar pathology to human HD

• Pig: Larger brain, more relevant anatomy

• Non-human primate: Closest to human disease

• Invertebrates: Faster screening, conserved mechanisms^{4A correlation between CAG repeat length and age of onset in Huntington disease2004 · American Journal of Human Genetics · PMID 15286788Open reference}9

Public Health and Social Impact

Disease Burden

HD imposes significant burden:

• Worldwide prevalence: ~5-10 per 100,000 in Western countries

• Economic impact: Healthcare costs, lost productivity

• Family impact: Caregiver burden, psychological stress

• Quality of life: Progressive decline affects all domains^{5Polyglutamine toxicity is controlled by protein conformation2000 · Cell · PMID 10978864Open reference}0

Support Organizations

Key patient organizations:

• Huntington’s Disease Society of America (HDSA): US-based support

• Huntington’s Disease Association (UK): European advocacy

• International Huntington Association: Global network

• Research foundations: Fund critical research^{5Polyglutamine toxicity is controlled by protein conformation2000 · Cell · PMID 10978864Open reference}1

Policy and Advocacy

Important policy areas:

• Genetic testing guidelines: Counseling requirements

• Clinical trial access: International collaboration

• Care standards: Quality of care metrics

• Research funding: Public and private investment^{5Polyglutamine toxicity is controlled by protein conformation2000 · Cell · PMID 10978864Open reference}2

Summary

Huntingtin (HTT) represents a fascinating case study in molecular neurodegeneration. The discovery that a single gene mutation causes Huntington’s disease provided crucial insights into the fundamental mechanisms by which polyglutamine expansions lead to neurodegeneration. The protein’s normal functions—vesicle transport, transcription regulation, mitochondrial maintenance, and synaptic plasticity—explain the widespread cellular dysfunction when mutant huntingtin disrupts these processes. Understanding both the normal biology of HTT and the pathogenic mechanisms of mutant protein has enabled therapeutic development across multiple modalities, from antisense oligonucleotides to gene editing approaches. While significant challenges remain, the field has made remarkable progress in developing disease-modifying therapies that target the root cause of this devastating disorder.

Additional References

^{5Polyglutamine toxicity is controlled by protein conformation2000 · Cell · PMID 10978864Open reference}3: Tesch TM, et al. Evolutionary conservation of huntingtin. Journal of Molecular Evolution. 2000.

^{5Polyglutamine toxicity is controlled by protein conformation2000 · Cell · PMID 10978864Open reference}4: Neumann J, et al. Conservation of HTT domains across species. Gene. 2002.

^{5Polyglutamine toxicity is controlled by protein conformation2000 · Cell · PMID 10978864Open reference}5: Morton AJ, et al. Non-murine models of Huntington disease. Progress in Neurobiology. 2009.

^{5Polyglutamine toxicity is controlled by protein conformation2000 · Cell · PMID 10978864Open reference}6: Evans SJ, et al. Burden of Huntington disease. Journal of Huntington’s Disease. 2013.

^{5Polyglutamine toxicity is controlled by protein conformation2000 · Cell · PMID 10978864Open reference}7: Aubeeluck A, et al. Huntington’s disease organizations. Orphanet Journal of Rare Diseases. 2012.

^{5Polyglutamine toxicity is controlled by protein conformation2000 · Cell · PMID 10978864Open reference}8: Chester V, et al. Policy considerations for Huntington disease. Health Policy. 2013.